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ABSTRACT: Drug penetration in human skin ex vivo following a modification of
skin barrier permeability is systematically investigated by scanning transmission X-ray
microscopy. Element-selective excitation is used in the O 1s regime for probing
quantitatively the penetration of topically applied rapamycin in different formulations
with a spatial resolution reaching <75 nm. The data were analyzed by a comparison of
two methods: (i) two-photon energies employing the Beer−Lambert law and (ii) a
singular value decomposition approach making use of the full spectral information in
each pixel of the X-ray micrographs. The latter approach yields local drug
concentrations more reliably and sensitively probed than the former. The present
results from both approaches indicate that rapamycin is not observed within the
stratum corneum of nontreated skin ex vivo, providing evidence for the observation
that this high-molecular-weight drug inefficiently penetrates intact skin. However,
rapamycin is observed to penetrate more efficiently the stratum corneum when
modifications of the skin barrier are induced by the topical pretreatment with the
serine protease trypsin for variable time periods ranging from 2 to 16 h. After the longest exposure time to serine protease, the drug
is even found in the viable epidermis. High-resolution micrographs indicate that the lipophilic drug preferably associates with
corneocytes, while signals found in the intercellular lipid compartment were less pronounced. This result is discussed in comparison
to previous work obtained from low-molecular-weight lipophilic drugs as well as polymer nanocarriers, which were found to
penetrate the intact stratum corneum exclusively via the lipid layers between the corneocytes. Also, the role of the tight junction
barrier in the stratum granulosum is briefly discussed with respect to modifications of the skin barrier induced by enhanced serine
protease activity, a phenomenon of clinical relevance in a range of inflammatory skin disorders.
■ INTRODUCTION
Topical drug delivery is an attractive way for administering
drugs dermally or transdermally, where the skin penetration
properties depend strongly on the physicochemical properties
of the drug and the formulation.1 The skin represents for most
drugs a barrier that has been investigated in detail by several
aspects, which include barrier disruption methods.2 The
stratum corneum (SC), the top horny layer of skin, plays a
key role in the barrier function of this organ.3 Of specific
interest are barrier disruptions caused by inflammatory skin
diseases, such as atopic dermatitis and psoriasis.4,5 Several
drugs have been used for the topical treatment of these
diseases, which include immunosuppressive macrolides, such
as cyclosporin A and tacrolimus. However, according to the
500 Da rule for skin penetration, high-molecular-weight drugs
have a limited skin penetration.6 Therefore, new formulations
have been developed to facilitate the dermal penetration of
such drugs.7
Rapamycin (sirolimus) C51H79NO13 (cf. inset of Figure 1) is
an FDA-approved macrocyclic lactone with anti-proliferative
properties used in cancer or immunosuppressive treatments,
for example, after organ transplantation.8 Related drugs, such
as everolimus, have been used for successful cancer therapy.9
Of specific interest is the topical application of rapamycin for
the treatment of facial angiofibromas,10,11 partially in
combination with other drugs, such as calcitriol.12 Short-term
efficacy and safety aspects of rapamycin gels for patients with
tuberous sclerosis complex have been investigated more
recently.13 Furthermore, human skin explants treated with
rapamycin were investigated in a culture medium revealing
histological changes and reduced keratinocyte proliferation.8
Rapamycin is known to act as a mammalian target of
Received: February 26, 2021
Accepted: April 7, 2021
Published: April 28, 2021
Articlehttp://pubs.acs.org/journal/acsodf




























































































rapamycin (mTOR) inhibitor,14−16 where the complexity of
the mTOR pathway has been reviewed before.17 Early work
was concerned with cellular transport and uptake studies of
this active substance, where the crucial parameters, such as
temperature and dose, were identified.18 Later work focused on
the role of rapamycin on immune cells.19 Of specific interest
has been the formulation of rapamycin for topical use, where
hydrophilic gels, ethanolic solutions, ointments, creams, and
formulations in petrolatum have been used.10,11 Dermal
penetration enhancers, such as ethanol,20 have also been
used for the preparation of rapamycin formulations, where the
long-term stability of such formulations has been evaluated as
well.11
The detection of topically applied drugs penetrated in the
different skin layers requires a method to probe low, ideally
therapeutically relevant, concentrations. Spectroscopic studies
need to be supplemented by microscopy approaches since the
drugs are inhomogeneously distributed in the biological matrix,
requiring the use of spectromicroscopy techniques. Multiple
combinations of such techniques have been developed in the
past and applied to biological matter. Often used are
fluorescence labels due to their specific response and high
sensitivity reaching single-molecule or -particle detection.21
Furthermore, super-resolution techniques below the diffraction
limit also increase significantly the detailed understanding of
processes occurring in biological matter.22 However, in the
field of drug delivery, it appears to be advantageous to avoid
labeling of drugs due to possible changes in their efficacy and
transport properties. This requires the use of label-free
detection schemes that have been developed over the last
decades. Such methods directly probe drugs or molecular
species of interest in the biological environment, including
human skin ex vivo.23 This is accomplished by exploiting their
unique molecular properties. For example, absorption in the
soft X-ray regime has been used in the past to probe with high-
sensitivity drugs in human skin explants or other biological
objects by scanning transmission X-ray microscopy
(STXM).24−28 Alternatively, Raman-based techniques have
been used,29−31 as well as atomic force microscopy (AFM)-
based approaches.32,33 Furthermore, mass spectrometry-based
approaches have also been used.23,34
This work aimed at investigating the skin penetration of
rapamycin in the skin with an intact or altered skin barrier.
This hydrophobic (log P = 4.3)35 and high-molecular-weight
(M = 914.187 g/mol)35 drug does not efficiently penetrate the
skin barrier if topically applied, as predicted by the 500 Da
rule.6,36,37 Nevertheless, penetration of rapamycin might be
enhanced by the serine protease trypsin. Trypsin applied in
moderate concentrations capable of triggering inflammatory
processes has been used as a stimulus in cell cultures to mimic
enhanced serine protease activity, typically found in inflam-
matory skin diseases, such as atopic dermatitis.38,39 It is also
known that trypsin-like serine proteases in the SC are
associated with desquamation.40 These proteases are found
to be more active in the outer SC than in the inner part of this
skin layer. Earlier studies on the proteolytic activity in the SC
indicate a linear temporal behavior in the range below 200
min.41 Furthermore, the epidermal barrier function of the skin
is known to depend on the serine protease CAP1/Prss8 in
mice, disturbing the lipid composition of the SC, the
corneocyte morphogenesis, and the processing of profilag-
grin.42 In humans, it is known that abnormal activity of serine
proteases leads to a loss in barrier function, such as in
ichthyosis. Furthermore, patients suffering from the Netherton
syndrome are known to have an increased serine protease
activity, leading to changes in barrier function, which is
accompanied by an altered SC lipid composition with a
preference for shorter chains and increased disorder of the
lipids.43,44 Recent work also highlights the increased drug
penetration in serine protease pretreated ex vivo skin models
with respect to the penetration of dexamethasone-loaded core-
multishell nanocarriers.39
■ EXPERIMENTAL SECTION
The ex vivo human skin samples from abdominal skin and
breast were obtained from different donors, who had agreed
prior to donation. The study has been run in accordance with
the Declaration of Helsinki guidelines and was approved by the
Ethics Committee of Charite́Universita ̈tsmedizin Berlin
(Germany) (approval EA1/135/06, renewed in January
2019). Skin was used within a few hours after surgery.
Subcutaneous fat was removed, and skin was cut in 1.5 × 1.5
cm squares. For serine protease treatment, the skin was first
cleaned with 50 μL of CHCl3/CH3OH (1:1) dropped on a
Finn chamber paper disc and placed for 1 min on the top of
the skin sample. Then, the skin was exposed to 20 μL of a 0.15
mg/mL solution of serine protease (pig pancreas trypsin,
Biochrom, Berlin, Germany) for different time periods (2, 4, 8,
and 16 h). Control skin samples were treated with 20 μL of
0.9% sterile saline. After incubation, the remaining solution was
removed from the skin surface by a cotton swab. The following
formulations were applied for systematic drug penetration
studies: (i) 40 μL/cm2 of a 2.5 μg/mL rapamycin solution in
36% ethanol, leading to a final amount of 100 μg/cm2
rapamycin deposited on the skin and incubated for variable
time periods (10, 100, and 1000 min, respectively); (ii) 50 μL/
cm2 of 8.5 mg/mL rapamycin dissolved in 70% ethanol and
2.5% hydroxyethyl cellulose (HEC) gel leading to a final
amount of 425 μg/cm2 deposited on the skin. Note that
previous work indicates that HEC gel does not change the
penetration properties, but it avoids drying of the drug on the
skin surface at long penetration times and high drug loads.25
Some of the skin samples exposed to the HEC gel formulation
were pretreated with trypsin for variable time periods (20 μL/
cm2 of a 0.15 μg/mL solution) of 2, 4, 8, and 16 h, respectively.
Similar to previous work, this pretreatment was performed to
model the enzymatic activity, cytokine environment, and
barrier alteration typical of inflamed skin.38,39 The samples
were treated with a cotton swab for removing the formulation
still sticking to the skin surface and subsequently prepared for
Figure 1. X-ray absorption cross section of rapamycin in the O 1s
regime. The inset (a) shows the O 1s → π* transition in greater
detail. The structure of rapamycin is shown in the top right corner.
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STXM studies by fixation in 2.5% glutaraldehyde and 1%
cacodylate buffer. Finally, they were embedded in EPON resin
(Serva, Heidelberg, Germany) and cut into 200−300 nm slices
with an area of typically 500 μm × 500 μm using an
ultramicrotome, similar to previous work.24−26,28,45−47 The
samples were deposited on silicon nitride (Si3N4) windows
(thickness: 100 nm, Silson, UK). All samples were charac-
terized by optical microscopy (MM-400/LU, Nikon) prior to
the STXM studies for selecting distinct regions to be
investigated. The thickness of the samples was subsequently
measured by AFM (nanoIR-2s, Anasys) in those regions that
were studied by STXM.
The STXM studies were performed at the beamline BL4U at
UVSOR-IIII Synchrotron (Institute for Molecular Science,
Okazaki, Japan).48 UVSOR-III is operated at 750 MeV and
300 mA in the top-up injection mode. The STXM (Research
Instruments, ex Bruker) at BL4U uses a Fresnel zone plate
(FZP, Applied Nanotools, Edmonton, Canada) as the focusing
optical element. The design of the FZP is optimized for the O
1s regime (520−565 eV). Its parameters are a diameter of 300
μm and an outermost zone width of 18 nm, and the nickel
pattern on a Si3N4 membrane substrate is 50 nm thick. The
focal length is 2.3 mm at 530 eV. The photon energy scale was
calibrated by the O 1s → π* transitions of CO2 and
dexamethasone.24,49 The energy resolution was adjusted by
the width of the slits of the X-ray monochromator of typically
50 μm, corresponding to an energy resolution of ∼60 meV at
the O 1s edge. The width of the slit also determines the
focusing spot size at the sample corresponding to 74 nm in the
O 1s regime. The STXM was operated in the on-the-fly mode
for scans with a squared pixel size of 250 nm for overview
images of the top skin layers, 100 nm for detailed scans of the
SC, and 30 nm for high-resolution scans at a dwell time per
pixel of 4 ms. Typical areas covered by each scan were 50 μm
× 10 μm, 20 μm × 5 μm, and 4 μm × 2 μm, respectively. The
soft X-ray monochromator was used with variable energy step
widths, covering 134 maps per stack of each experiment
between 520 and 565 eV. This allows us to have sufficiently
small energy steps of 0.1 eV for gathering the near-edge
features, whereas in the pre-edge- and post-edge-continua, the
energy step width varied between 0.5 and 0.607 eV,
respectively. This approach is different from our previous
work, where only a few photon energies were selected during
the experiments due to long data acquisition times and limited
beam time.24−26 As a result, the analysis of the optimum X-ray
contrast can be done in the present experiments during the
detailed data analysis, that is, after the beam time. Radiation
damage is only observed for repeated scans at the same
location, as evidenced by bleaching of the samples in multiple
scanned areas.
Positional shift of the raw stacks of X-ray absorption spectra
was corrected for lateral drifts using the Zimba tool in the
aXis2000 program.50 Small energy shifts of the order of <200
meV, occurring during data acquisition of the spectral stacks,
were identified from the total absorption signal using the
known X-ray absorption of dexamethasone.24 These correc-
tions were considered for both approaches of data evaluation
outlined in the following so that the results can be compared to
each other, especially since they are extracted from the same
raw data. The optical density ln(I0/I) can be used to determine
the local concentration and the fraction of penetrated drug
relative to the topically applied drug, according to the Beer−
Figure 2. Penetration of rapamycin dissolved in ethanol (100 μg/cm2) topically applied to human SC ex vivo. Top: X-ray micrograph at 532.03 eV
(white color corresponds to high transmission, black color to low transmission, see also included scheme of grayscale between the minimum (min)
and maximum (max) of X-ray transmission), middle: rapamycin distribution as a function of skin depth at the same depth scale as the X-ray
micrographs using 531.14 and 530.74 eV (approach 1, labeled ①); bottom: results from singular value decomposition (approach 2, labeled ②): (a)
10 min penetration time; (b) 100 min penetration time; and (c) 1000 min penetration time. The dashed thin white lines in the micrographs mark
the top of the SC, that is, the skin surface is on the right-hand side. In (c), the top of the VE is also marked by another white dashed line. The scale
bars correspond to 4 μm. The skin surface at the top edge of each micrograph is chosen as the reference of the depth scale. Horizontal black dashed
lines are used to guide the eye for the depth profiles of rapamycin. The minimum (min) and maximum (max) correspond to (a) 80,000 and
175,000; (b) 68,500 and 179,500; (c) 67,000 and 127,500 counts/s, respectively.
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Lambert law, similar to previous work:24−26,47 ln(I0/I) = σ·c·d,
where I0 is the intensity of the incident photons, I is the
intensity of the transmitted photons, σ is the absorption cross
section (in Mbarn, 1 Mbarn corresponds to 10−18 cm2, see
Figure 1), c is the concentration of the absorber, and d is the
thickness of the sample absorbing X-rays, as determined by
AFM. I0 is obtained from appropriate reference spectra, that is,
the transmitted radiation without the absorbing skin sample in
the photon beam. Reference spectra were frequently recorded
for taking any temporal changes in photon flux into account.
Absolute absorption cross sections were derived at 560 eV
using tabulated reference data.51
The STXM data were analyzed in two different ways, where
the former is similar to previous work,24−26,47 by using two-
photon energies, where the X-ray absorption cross section of
the species to be detected is different and can be distinguished
from the fixed skin matrix through its absorption cross section
and chemical shift even in small concentrations. This
corresponds to approach 1 and is also labeled as ① in Figures
2−4. For probing rapamycin, we used the photon energies
531.13 and 530.73 eV (cf. Figure 1). These energies turned out
to be the most sensitive for probing the drug in fixed human
skin. Small changes in photon energy occurring during data
acquisition, which are due to slight changes in optical element
position in the monochromator or electron beam position in
the storage ring, were corrected for the data stacks evaluated.
These photon energies yield for rapamycin a change in
absorption cross section of 6 ± 0.5 Mbarn (cf. Figure 1),
whereas the absorption cross sections of EPON resin and fixed
skin remain fairly constant at both photon energies.
Alternatively, the O 1s spectral shapes of the different
components contributing to the X-ray absorption signal have
been deconvoluted using a linear combination of a limited
number of spectral components of the major species contained
in the skin samples, requiring reliable reference spectra for
Figure 3. Penetration of rapamycin dissolved in HEC gel (rapamycin: 425 μg/cm2 topically applied to the skin for 24 h). Top: X-ray micrographs
at 532.03 eV; middle (approach 1, labeled ①): rapamycin distributions as a function of skin depth on the same length scale as the X-ray
micrographs using the same photon energies as specified in Figure 2; bottom (approach 2, labeled ②): rapamycin distributions derived from
singular value decomposition as a function of skin depth on the same length scale as the X-ray micrographs: (a) 2 h primary preparation with serine
protease; (b) 4 h primary preparation with serine protease; (c) 8 h primary preparation with serine protease; and (d) 16 h primary preparation with
serine protease. The vertical dashed thin white line on the right-hand side of each micrograph marks the skin surface. The left vertical dashed line
corresponds to the top of the VE, which is located below the SC. The scale bar corresponds to 10 μm. The skin surface at the top edge of each
micrograph is chosen as the reference of the depth scale. The dashed black horizontal lines in the rapamycin distributions as a function of depth are
inserted to guide the eye. The minimum (min) and maximum (max) correspond to (a) 970,000 and 1,385,000; (b) 900,000 and 1,315,000; (c)
980,000 and 1,365,000; and (d) 942,500 and 1,445,000 counts/s, respectively.
Figure 4. (a) High-resolution X-ray micrograph recorded at 532.03
eV in the SC of a skin sample exposed for 16 h to trypsin and
subsequently for 1000 min to an ethanolic rapamycin solution. Lipid
layers are marked by L and corneocytes by C. Pixel size: 30 nm2; the
scale bar corresponds to 800 nm. The skin surface is chosen as the
reference of the depth scale. (b) Integrated intensity of the rapamycin
concentration on the same length scale as the micrograph using
approach 1 (labeled ①) and (c) integrated intensity of the rapamycin
concentration on the same length scale as the micrograph using
approach 2 (labeled ②). The minimum (min) and maximum (max)
correspond to 246,000 and 472,000 counts/s, respectively.
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these major species in the investigated samples. It is similar to
that used along with STXM, for example, for analyzing
polymer blends.52 We also note that there are also program
packages, such as MANTiS, available.53 However, the present
analysis goes beyond with respect to the control of parameters,
such as avoidance of negative concentrations and exact energy
calibration of the data stacks and reference spectra, which is
crucial for the identification of low concentrations of the
penetrated drug. This approach 2 is labeled as ② in Figures
2−4. It is evident that the fixed skin contains a large number of
chemical compounds, which cannot be considered by such an
approach. Therefore, we grouped them together as follows: (i)
rapamycin, the drug to be identified; (ii) human skin, which
varies its composition as a function of depth. Therefore, these
variations are considered by changes in cross section in the O
1s → π* and O 1s → σ* regimes. These quantities reflect local
changes in skin composition which vary due to a different
degree of unsaturated and saturated moieties in the skin
samples probed by element-specific O 1s excitation, for
example, accounting for different chemical compositions in
the SC, where corneocytes and the lipid lamellae have different
X-ray absorption spectra, as well as the viable epidermis (VE);
and (iii) EPON resin, which is used for embedding the skin
samples. These reference spectra are shown in the Supporting
Information (see Figure S1). This implies that the interactions
between the biological matrix and the drug do not have any
significant influence on the shape of the X-ray absorption
spectra.
The weight factors of the individual components of data
analysis in approach 2 were obtained from a program written
in Igor Pro 8 (WaveMetrics, Lake Oswego, OR, U.S.A.) using a
Levenberg−Marquardt algorithm that minimizes the devia-
tions of the weighted sum of the reference spectra from the
experimental absorption spectrum contained in each pixel.
From these weight factors, the local concentrations of the
major components are derived by considering the local
thickness of the sample, which was determined from
supplementary AFM measurements. Significant changes in
skin thickness were especially probed in the SC, where
corneocytes are often thicker than the lipid regions between
them. This is accomplished by measuring the height of the
EPON resin by AFM in the same regions scanned by STXM.
As a result, one can derive the local concentration of the drug
rapamycin in the skin sections under study using both
approaches. Finally, penetration profiles of rapamycin were
derived by integrating each line of the maps, corresponding to
a given depth below the skin surface, for each component.
Here, we focus on the local drug distribution, but this
approach can also be applied to any component contained in
the skin sections. Note that approach 2 is more sensitive to
spatial drifts of the sample due to the substantial data
acquisition times, which range typically between 30 and 60 min
per stack. This is different from approach 1, in which the
energies used for probing rapamycin are only separated by 400
meV so that in this case, no spatial shifts of the sample occur.
■ RESULTS AND DISCUSSION
Figure 1 shows the absorption cross section of rapamycin in
the O 1s regime along with its structure (C51H79NO13, M =
914.17 g/mol, see the inset of Figure 1). This is the origin of
selective and quantitative probing of this drug. The absolute
absorption cross-sectional scale is calibrated at 560 eV, that is,
far above the broad O 1s → σ* transition, where the
continuum cross section dominates using the known atomic
absorption cross section according to tabulated data.51 Note
that the underlying cross section from the valence shell as well
as the C 1s and N 1s continua has been subtracted so that only
the O 1s specific cross section is shown in Figure 1.
The spectral features of selective O 1s excitation are
reported, indicating an intense and slightly asymmetric O 1s→
π* transition peaking at 531.2 eV [see Figure 1, inset (a)].
This feature is slightly asymmetrically broadened due to
different chemical shifts at different carbonyl and carboxyl
sites.49,54 The lower energy part of this resonance at 531.13 eV
is used for selective probing of rapamycin in human skin. This
is essentially due to the carbonyl oxygen sites, similar to
previous work on dexamethasone.24 The carboxyl site is
expected to occur at the high energy part of the O 1s → π*
-resonance.49 The other intense feature is the broad O 1s→ σ*
transition peaking at 539.5 eV with an absorption cross section
of 15 Mbarn.
Figure 2 shows a series of X-ray micrographs taken at 532.03
eV at the top of each figure, where the transmitted X-rays
provide the contrast. This photon energy was chosen due to its
high X-ray contrast, visualizing the structural features of the
top skin layers, mostly showing the SC with its stratified
structure of corneocytes. Note that the skin surface is located
on the right-hand side and the depth increases to the left. This
orientation of the skin samples was chosen for instrumental
reasons so that during data acquisition, each line scanned
horizontally corresponds to a depth profile. Only for 1000 min
penetration time, the stratified structures appear to be
significantly thinner (see Figure 2c), which is most likely due
to alterations of this top skin layer as a result of the long
penetration time and exposure to the drug formulation
containing ethanol. The thin white structures in the SC
correspond to the lipid layers between the corneocytes. They
can be as thin as ∼100 nm and have been easily resolved by
high-resolution scans of STXM.25 Previous work has indicated
that in these layers most hydrophobic drugs, such as
dexamethasone, were found, whereas no drugs were found in
the corneocytes.25 Similarly, we would expect that rapamycin
should also be preferably found in these lipid layers, even if
drug penetration is inefficient. The reason for this expectation
is that rapamycin has even higher octanol−water distribution
coefficient log P (log P = 4.3)35 than dexamethasone (log P =
1.83).35 The penetration time of the topically applied ethanolic
rapamycin solution depositing 100 μg/cm2 of the drug is
varied ranging from 10 (a) over 100 (b) to 1000 min (c).
Rapamycin is probed in the graphs marked by ① according to
approach 1, that is, at 531.13 and 530.73 eV (see Experimental
Section). Then, these changes in optical density, recorded at
both photon energies, are subtracted pixel by pixel and
subsequently integrated line by line, that is, as a function of
depth. This yields, on a relative scale, the drug concentration as
a function of depth (labeled ① in Figure 2a−c). These signals
appear to be flat and noisy, similar to previous work, if no drug
has penetrated the skin.24,25,47 We note that the topically
deposited drug concentration was not too low to be detected
since, in other experiments communicated below, the topically
applied ethanol solution of rapamycin is clearly detected after
primary treatment with serine protease.
None of the integrated signals, corresponding to the local
rapamycin concentration as a function of depth, shows any
evidence for a local increase in drug concentration, which
means that the drug is not probed by approach 1 no matter
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how long the intact skin is exposed to the drug formulation,
that is, t ≤ 16 h. The same result is obtained from the singular
value decomposition (approach 2), marked by ② in Figure 2.
Only small differences occur between both approaches, for
example, in Figure 2b; a distinct minimum, corresponding to a
defect in the skin, is observed more distinctly using approach 1,
but it is less pronounced in approach 2. Overall, both
approaches used to evaluate the penetration of ethanolic
rapamycin solution yield the same result, that is, no drug
penetrated intact skin if the penetration time of the ethanolic
drug solution is increased up to 1000 min. This result is
remarkable since it is known that ethanol is not only the
solvent for rapamycin, but it also acts as a penetration
enhancer.20 These results serve as an important benchmark for
determining the role of serine protease with respect to changes
in penetration properties of rapamycin and the accompanied
changes in the skin barrier, which are discussed in the
following.
Figure 3 shows the results of a series of experiments,
covering the SC and the top part of the VE, in which the skin
was topically pretreated with the serine protease trypsin for
defined time periods ranging between 2 and 16 h.
Subsequently, the HEC gel drug formulation was topically
applied to the prepared skin sections for 24 h (1440 min) at a
concentration of 425 μg/cm2. Rapamycin was probed in the
same way as shown in Figure 2, that is, by approaches 1 and 2.
The results shown in Figure 3a clearly indicate that after 2 h of
pretreatment with trypsin, there is from both approaches a
visible enhancement of rapamycin in the SC, whereas, in the
VE, no drug is observed, as visualized by a horizontal dashed
line for both approaches. Note that the drug distributions
derived from these approaches are similar but not identical.
The signal-to-noise ratio from the evaluation employing
approach 1 is lower, and the drug appears to be more
continuously distributed in the entire SC, whereas the drug
distribution derived from singular value decomposition
(approach 2) is substantially more pronounced, as indicated
by a higher signal-to-noise level in the local drug concen-
tration. This finding is explained by the fact that approach 2
makes use of the entire spectral data gathered in the O 1s-
regime, whereas approach 1 only considers two-photon
energies.
Circular structures are observable in the VE and are due to
the nuclei of keratinocytes. These are not involved in drug
uptake, since it is likely that the tight junction barrier remains
intact after 2 h exposure to trypsin. This result is ascribed to
the efficacy of trypsin to alter the barrier of the top skin layer at
least after a short treatment time of the SC (e.g., 2−8 h),
allowing rapamycin to enter only this top skin layer. The sharp
minimum in local drug concentration probed by both
approaches 1 and 2 near the skin surface is due to a loose
layer of corneocytes (see Figure 3a) that is not any more
connected to the compact SC.
There are some differences in drug distribution derived from
both approaches. Approach 1 yields a noisy and continuous
drug distribution, whereas from approach 2, detailed structures
are derived. Even at a low spatial resolution, it is evident that
the local maxima in rapamycin concentrations are observed in
the corneocytes, especially in the lower SC, whereas minima
are connected with the lipid layers between the corneocytes.
This result is quite unexpected as compared to previous work
on dexamethasone, which was exclusively found in the lipid
layers.25 Also, polymer core-multishell nanocarriers with sizes
below 10 nm were also observed in these thin lipid layers.26
We rationalize the present result in terms of a significant loss
of the integrity of the upper SC induced by trypsin in the top
skin barrier. This is connected to the structure of corneocytes
where a thin corneocyte lipid envelope and a cornified cell
envelope are present inside the intercellular lipid layers.55
Earlier NMR studies have indicated that the lipids are
covalently bound to the protein envelope.56 Inside the
corneocyte keratins, filaggrins and their degradation products
are found, consisting of serine, glycine, and glutamine in
filaggrins.57 It appears to be straightforward to assume that a
loss of the thin corneocyte envelope barrier induced by serine
protease will provide access to trypsin to the bulk interior of
the corneocytes to cleaving the serine moieties, which are
known to contribute to 25.3% of the filaggrin.57 The
subsequently applied rapamycin formulation can then pene-
trate corneocytes. As a consequence, rapamycin can penetrate
the entire SC but not the VE after 2 h of exposure to trypsin,
implying that the tight junction barrier in the stratum
granulosum remains still intact. We also observe an increase
in drug concentration right above the skin surface. This is
ascribed to residues of the drug that is still sticking to the skin
surface and is not fully removed by a cotton swab done prior to
fixation of the skin samples. This situation is not significantly
different if the exposure time to trypsin is increased to 4 and 8
h (see Figure 3b,c), respectively. The SC appears to be
specifically thin in the analyzed region of Figure 3b. Therefore,
the amount of the drug appears to be low, but there is also no
drug observed in the VE via approaches 1 and 2. In the sample,
corresponding to 8 h of trypsin exposure shown in Figure 3c,
the drug is broadly distributed over the SC, as follows from
both approaches. However, in the lowest part of this layer,
apparently no or little drug is found. These variations observed
for the samples analyzed in Figure 3b,c can be due to local
variability of trypsin and subsequent drug applications that
cannot be easily controlled prior to analysis, even though the
same protocol was followed. This situation appears to be
different after 16 h exposure to trypsin (see Figure 3d). The
drug is broadly spread, but the distribution is rather
homogeneous not only in the SC but also in the VE, as
follows from both approaches of data analysis. Spatially
resolved results from approach 2 indicate that rapamycin is
diffusely spread over the top part of the VE (see also
Supporting Information, Figure S8a). This implies that longer
time periods of serine protease treatment may be associated
with damage to the tight junctions, which are known to be
located in the stratum granulosum, by trypsin, so that
rapamycin can penetrate to deeper skin layers. More
specifically, the tight junctions of the stratum granulosum
contain occludin.58 This protein contains serine moieties,59
which can be affected by trypsin. This suggests that diffusive
penetration of topically applied trypsin takes more than 8 h to
reach and disturb the tight junctions in the stratum
granusolum. The present finding is also consistent with earlier
ones that drug penetration is enhanced in inflamed skin.60
However, this is different from studies on the penetration of
polymer nanocarriers that were not affected by inflammation.61
Figure 4a shows a high-resolution X-ray micrograph taken in
the middle of the SC recorded at 532.03 eV. This skin sample
has been exposed for 16 h to trypsin and subsequently for 1000
min to an ethanolic rapamycin solution (100 μg/cm2). Note
that without the pretreatment with trypsin, no drug
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penetration was observed under these conditions (cf. Figure
2c). Pretreatment of the skin samples with serine protease is
evidently of importance for rapamycin penetration, as was
shown in the results shown in Figure 3. This means that the
drug formulation is of minor importance for drug penetration.
Figure 4a shows corneocytes (C) (gray areas) and the vertical
less absorbing bright thin regions are attributed to the lipid
layers (L) separating the corneocytes. Their internal structure
is known from high-resolution electron microscopy37,62 but
cannot be fully resolved by STXM.25 Figure 4b,c shows the
integrated intensity of the rapamycin concentration in this part
of the skin sample using approaches 1 and 2, respectively.
Both approaches yield the same result for the lipid structures
with a width ranging between 130 and 300 nm. The minima in
local rapamycin concentration coincide with the prominent
lipid structures, whereas the highest local drug concentration is
found in the area of corneocytes. This result underscores the
conclusions derived from low spatial resolution studies (see
Figure 3) and is unlike the expectation that lipophilic drugs
should be preferentially located in the lipid layers, as was
observed for dexamethasone from X-ray microscopy.25
Evidently, the corneocytes become accessible to drug
penetration via the pretreatment with trypsin. The present
results also suggest that there is a diffusive transport from the
lipid layers between the corneocytes into the bulk interior of
the corneocytes so that the concentration in the lipid layers is
decreased. The exact details of these changes are not clear to
the best of our knowledge and require further work.
Finally, the amount of the penetrated rapamycin is
quantified using approaches 1 and 2 of data evaluation since
X-ray microscopy provides quantitative information on dermal
drug penetration.24−26 The mass of the applied drug was
always 425 ± 5 μg/cm2. According to approach 1, the integrals
of the relative drug intensities shown in Figure 3 are used,
yielding the mass of the drug penetrating the skin samples.
Similarly, approach 2 is also used for determining the drug
uptake into the skin samples. Here, the relative weight factors
are used accordingly. The results are shown on a relative scale
in percent of the topically applied rapamycin that is found in
the top skin layers (see Table 1), which can be easily
transferred to an absolute mass scale by considering the
topically applied amount of the drug. In general, both
approaches yield a similar temporal evolution, even though
the relative uptake derived from approach 1 appears to be
systematically somewhat smaller than those derived from
approach 2. The higher values from approach 2 are considered
to be more reliable since the entire spectral information is used
for evaluation, rather than two micrographs taken at close-lying
photon energies. We also conclude from this result that earlier
work derived according to approach 1 can also be considered
to be correct.24−26,47 However, approach 2 appears to be
preferred, specifically for highly dilute absorbers that have no
chemical shift of the resonant transitions, such as the O 1s →
π* transition compared to the majority species, that is, EPON
resin and the skin matrix. Further evidence for this conclusion
comes from supplementary work on model skin, where the
results from STXM were compared to other analytical
approaches.46 The present results also indicate that a distinctly
lower drug uptake is derived for the sample that was exposed
for 4 h to serine protease, where the SC is significantly thinner
than for the other samples (see Figure 3). If normalized to the
thickness of the SC, one derives for this sample an almost
identical value as for the other ones at 2 and 8 h. As a result, no
clear trend is observed for the investigated treatment times
with serine protease. This may imply that 2 h of trypsin
treatment prior to topical drug penetration are sufficient to
make the SC accessible to rapamycin, whereas longer times
periods are required to damage the tight junction barrier so
that rapamycin can even penetrate the VE, as observed for 16 h
pretreatment with trypsin, which yields the highest drug uptake
for both approaches. Compared to the ethanolic formulation
without trypsin pretreatment that does not show any increase
in local drug concentration near the skin surface, we can
conclude that the serine protease trypsin increases the drug
penetration of rapamycin significantly with a drug uptake
reaching 58 ± 2% at 16 h of pretreatment time as derived from
approach 2 and 42 ± 5% according to approach 1. This implies
that drugs exceeding the 500 Da limit can be absorbed in the
skin if the skin barrier is significantly weakened. This
underscores that treatment with serine protease is suitable to
simulate inflammations in skin samples ex vivo.
■ CONCLUSIONS
The present results indicate that STXM is capable of probing
selectively and quantitatively the immunosuppressive drug
rapamycin in human skin ex vivo. This is possible on the one
hand due to a slight chemical shift of the O 1s → π* transition
of rapamycin, which is different from that of the other majority
species contained in fixed human skin. On the other hand, the
approach of singular value decomposition makes use of the full
spectral information gathered in each pixel of the X-ray
micrographs and yields comparable results to the other
approach. This work is from the methodological point of
view primarily devoted to demonstrating the equivalence of
both approaches of data evaluation. However, the full potential
of singular value decomposition is exploited, if the drug or
other species of interest shows no chemical shifts relative to the
majority species contained in fixed skin so that it becomes
impossible to use just two-photon energies, corresponding to
approach 1. Such studies go beyond the scope of this work and
will be the subject of subsequent work.
From the dermatological point of view, it is shown that an
ethanolic drug solution does not increase the skin penetration
of a lipophilic high-molecular-weight drug, which is fully
consistent with the 500 Da rule. Topically applied rapamycin
only penetrates intact human skin, if the skin barrier is
weakened by pretreatment with the serine protease trypsin.
Upon enzymatic disruption of the SC barrier, the topically
applied drug is mostly distributed in the SC. High spatial
resolution experiments indicate that rapamycin is primarily
found in corneocytes but not in the lipid layers between the
Table 1. Fraction of the Topically Applied Rapamycin to
Human Skin after Modification of the Skin Barrier by the
Serine Protease Trypsin for Variable Time Periods,
















in skin [%] by
approach 2
2 425 ± 5 31 ± 5 43 ± 6
4 425 ± 5 11 ± 5 11 ± 2
8 425 ± 5 32 ± 5 44 ± 7
16 425 ± 5 42 ± 5 58 ± 2
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corneocytes. This behavior is rationalized in terms of chemical
changes to the skin lipids and corneocytes induced by serine
protease. Furthermore, long exposure times to trypsin indicate
that rapamycin can also penetrate the VE. Further experiments
will investigate if this result can be assigned to the damage of
the tight junction barrier, which requires serine protease
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Singular value decomposition, reference spectra, and
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